News

Clinicians have begun to incorporate more holistic ways to approach the treatment of multiple sclerosis symptoms by focusing on better overall health, exercising, and dieting.

New data for the Rocket Pharmaceutical gene therapy candidate show durable benefit in patients 6 months out from transplant.

The global biopharmaceutical company released research data on rozanolixizumab and zilucoplan at the 2021 ASH annual meeting and exposition.

An international assessment shows many patients are wary of emergency rooms, and clinicians want more diverse therapies.

Data show 12 of 25 strokes (48%) in a cohort of children did not met the definition of typical stroke related to sickle cell cerebral vasculopathy.

Data from phase 1 and phase 2 of the Alta study was presented at ASH this weekend.

Defined roles and research-informed recommendations are lacking for clinicians navigating birth control with females with sickle cell.

Investigators suggested this approach will allow for comprehensive mapping of the genomic landscape and clonal evolution of stem cells in sickle cell patients

Patients with sickle cell disease often suffer from acute kidney injuries and chronic kidney disease.

An ongoing assessment of caregivers considering hydroxyurea initiation for children with sickle cell disease provides a look into how such families are handling telemedicine and the pandemic.

Data show the average maximum cortical capillary RBC velocity is significantly greater in sickle cell mice compared to controls.

New ASH 2021 data shows how guidance is still lacking for clinicians responsible for addressing contraception with women with sickle cell disease.

Dr. Amy Paller and colleagues noted high efficacy rates and minimal adverse events from biologic therapy.

At least 3 companies have presented later phase data on live microbiota therapies for treating recurrent C difficile infections in 2021.

Though seasonal flu activity has remained low, the number of influenza virus detections reported by clinical and public health laboratories had increased in recent weeks.

New data from the CDC highlights the need to mitigate the potential severity of the influenza season, particularly with COVID-19's substantial impact on care systems.

Prior to the study, little was known on the relationship between the disease and fractures.

Investigators suggested systemic mental health monitoring could be beneficial for women who have atopic disease before pregnancy.

The data shows booster shots offer particularly strong protection against the variant.

Among vaccinated individuals, results show a 90% lower mortality rate due to COVID-19 in the group that received a booster compared with those who did not.

Investigators called for more studies which feature adequately powered trials of test-guided dietary exclusions.

The cumulative probability of death was 26% at day 7 and increased to 53% at day 21.

New data from the Liberty Asthma VOYAGE study saw fewer asthma exacerbations and improved lung function in this patient population.

The topical drug was associated with adverse events that were mainly localized to the application site and mild to moderate in nature.

The US recommended HBV vaccines to be part of the infant immunization plan in 1991.

The first approval for the novel device was met with acclaim in the field this year. Now, specialists want to see how their colleagues will implement it.

In a recent clinical trial, Evusheld recipients at increased risk of severe COVID-19 infection saw a 77% reduced risk of developing COVID-19.

Donald Alcendor, PhD, joins to review currently available data surrounding the newest COVID-19 variant of concern, and shares guidance for concerned clinicians and the general public.